AI is increasingly viewed as a major opportunity for biotech and healthcare, with potential gains across AI drug discovery, AI-driven diagnostics and screening, and AI-powered hyper-personalized medicine. “Dry labs” using simulations instead of wet-lab experiments could shift how biotech work is done. Biotech has often been treated as speculative and less predictable, but AI benefits could improve investability and reduce uncertainty. The timing of a breakthrough moment for biological AI remains unclear, but some biotech stocks are described as undervalued for investors seeking lower volatility, solid growth, and exposure to AI. Two biotech companies are presented as candidates quietly adopting AI to develop future blockbuster therapies.
"If you're looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech innovators. Indeed, we've heard a lot about the promise of AI when applied to the field of biotechnology and healthcare."
"From cancer treatments and curing a long list of diseases, perhaps there is no bigger win to be had from AI than within the health sector. Whether we're talking about AI drug discovery, AI-driven diagnostics and screening, or even AI-powered hyper-personalized medicine, there's a ton of promise as AI comes for biotech. With the rise of "dry labs" (think simulations over actually running experiments by mixing chemicals), perhaps the biotech landscape could shift in a profound way."
"Undoubtedly, the biotech scene is seen more as a less-predictable, perhaps more speculative playground for traders than a place where there's a great deal of certainty. If AI delivers on its promise, perhaps biotech could become far more investable, which, in turn, could make some of the names worth heftier premiums. For now, biological AI is in its very early innings, and it's hard to know when the ChatGPT moment will come for the field."
"Either way, though, I still think the names are looking cheap these days, especially for investors looking for lower betas, solid growth, and underrated AI exposure. In this piece, we'll look at two biotech names that could be worth a closer look as they quietly adopt AI to help produce the next big blockbuster. I have no idea when the Mythos of biotech will arrive, but when it does, I think it'll be tough to ignore the biotech innovators."
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]